|1.27||-0.0200||-1.55%||Vol 20.82K||1Y Perf -6.52%|
|Jan 27th, 2023 15:43 DELAYED|
|- -||- -%|
|Target Price||8.67||Analyst Rating||Strong Buy 1.00|
|Potential %||582.68||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||36.74||Earnings Rating||Sell|
|Market Cap||36.36M||Earnings Date||24th Mar 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||24th Mar 2023|
|Estimated EPS Next Report||-0.28|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||49.33K|
|Avg. Monthly Volume||65.50K|
|Avg. Quarterly Volume||99.32K|
Moleculin Biotech Inc. (NASDAQ: MBRX) stock closed at 1.27 per share at the end of the most recent trading day (a -1.55% change compared to the prior day closing price) with a volume of 20.82K shares and market capitalization of 36.36M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 15 people. Moleculin Biotech Inc. CEO is Walter V. Klemp.
The one-year performance of Moleculin Biotech Inc. stock is -6.52%, while year-to-date (YTD) performance is 19.81%. MBRX stock has a five-year performance of -89.26%. Its 52-week range is between 0.817 and 2.05, which gives MBRX stock a 52-week price range ratio of 36.74%
Moleculin Biotech Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 0.59, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -35.70%, a ROC of -35.74% and a ROE of -39.42%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Moleculin Biotech Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Moleculin Biotech Inc.’s next earnings report date is 24th Mar 2023.
The consensus rating of Wall Street analysts for Moleculin Biotech Inc. is Strong Buy (1), with a target price of $8.67, which is +582.68% compared to the current price. The earnings rating for Moleculin Biotech Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Moleculin Biotech Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Moleculin Biotech Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 31.54, ATR14 : 0.08, CCI20 : 58.61, Chaikin Money Flow : 0.08, MACD : 0.02, Money Flow Index : 54.14, ROC : 8.55, RSI : 52.38, STOCH (14,3) : 57.87, STOCH RSI : 0.46, UO : 50.87, Williams %R : -42.13), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Moleculin Biotech Inc. in the last 12-months were: Jonathan P. Foster (Option Excercise at a value of $0), Walter V. Klemp (Buy at a value of $83 498), Walter V. Klemp (Option Excercise at a value of $0)
Sat, 12 Nov 2022 12:15 GMT Moleculin Biotech (MBRX) Receives a Buy from Maxim Group- TipRanks. All rights reserved.
Wed, 28 Sep 2022 16:30 GMT Analysts Top Healthcare Picks: Ocugen (OCGN), Moleculin Biotech (MBRX)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.